← Back to Search

Chemotherapy

1 for Stomach Cancer (FR-WB-TT/che Trial)

Phase 2
Waitlist Available
Led By Joan M Bull, M.D.
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

FR-WB-TT/che Trial Summary

Thermal therapy (hyperthermia, or heat) increases chemotherapy cancer cell kill. By itself, thermal therapy can also kill cancer cells. Whole body thermal therapy is a systemic treatment; whole-body fever-range thermal therapy can safely treat cancer cells wherever they are throughout the entire body. In this study, we are testing the combination of fever-range heat treatment and chemotherapy to test 1) The response of three types of cancer (small-cell lung, neuroendocrine cancer, lung cancer, and gastric cancer) to the thermo-chemotherapy improves cancer response compared to the effect of only chemotherapy drugs in current use; 2) whether the thermo-chemotherapy treatment helps the person's own body fight the cancer cells; and 3) whether this treatment is safe and comfortable for the patient. This study does not offer heat treatment alone. Any patient with inoperable or metastatic small cell lung cancer, neuroendocrine cancer (any organ), gastric cancer, or lung cancer, can be treated with the Phase II protocol therapy; however, the patient will need to undergo selected medical tests to make sure this treatment would be safe for them.

Eligible Conditions
  • Stomach Cancer
  • Neuroendocrine Cancer
  • Small Cell Lung Cancer
  • Non-Small Cell Lung Cancer

FR-WB-TT/che Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Response Duration
Survival
Tumor Response by RECIST criteria (CR+PR)
Secondary outcome measures
Quality of Life
Toxicity

FR-WB-TT/che Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment2 Interventions
Thermochemotherapy

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
905 Previous Clinical Trials
321,078 Total Patients Enrolled
Joan M Bull, M.D.Principal InvestigatorThe University of Texas Health Science Center, Houston
2 Previous Clinical Trials
60 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby May 2025